Search results for "DYAX"

REFINE RESULTS

SEARCH RESULTS

About 2 results. Sort By: Date | Relevance
UPDATE 2-Drugmaker Shire delivers earnings beat amid deal-making push

LONDON, Feb 11- Drugmaker Shire reported better-than-expected profit in the last quarter of 2015, a period when management could have been distracted by buying rare disease specialist Dyax and the final stages of its $32 billion pursuit of Baxalta International. Shares in the London- listed company reversed early losses on Thursday to trade up 0.7 percent at...
Source: Reuters | By: Paul Sandle
UPDATE 3-BioCryst shares tumble after genetic disorder drug fails study

*Drug fails to beat placebo in mid-stage trial. Feb 8- BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, sending its shares skidding as much as 68 percent in early trading on Monday. The results will clearly work in the favor of British drugmaker Shire Plc, which has two...
Source: Reuters